Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + cetuximab + cisplatin + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This combination involves **tislelizumab**, an anti-PD-1 monoclonal antibody that enhances T-cell function by blocking PD-1 signaling; **cetuximab**, an EGFR inhibitor used in treating colorectal and head and neck cancers; **cisplatin**, a platinum-based chemotherapy agent; and **nab-paclitaxel**, a formulation of paclitaxel that improves solubility and delivery. The combination is likely used for advanced cancers, leveraging both immunotherapy and chemotherapy.
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)EGFR T790M (Epidermal growth factor receptor T790M mutant)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on tislelizumab + cetuximab + cisplatin + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + cetuximab + cisplatin + nab-paclitaxel.